Nottem (Zolpidem Tartrate)

Zolpidem Tartrate belongs to the non‑benzodiazepine hypnotic class and is used to manage sleep‑related disorders.

• Insomnia (difficulty initiating sleep): helps patients fall asleep more quickly.
• Short‑term insomnia: provides temporary relief of sleep onset problems for up to four weeks.
• Sleep‑onset insomnia: improves the ability to start sleeping after going to bed.

• Zolpidem Tartrate acts as a positive allosteric modulator at the GABA‑A receptor complex, binding preferentially to the α1 subunit. This enhances the inhibitory effect of GABA, increasing chloride influx and producing a sedative‑hypnotic response that facilitates the initiation of sleep without the broader muscle relaxant effects seen with benzodiazepines.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Drowsiness or excessive daytime sleepiness
• Dizziness or light‑headedness
• Headache
• Unpleasant taste or dry mouth
• Nausea or gastrointestinal discomfort
• Short‑term memory impairment

Serious or Rare Side Effects

• Complex sleep behaviors such as sleepwalking or driving while asleep
• Allergic reactions including rash, itching, or swelling
• Depression or emergence of suicidal thoughts
• Respiratory depression, especially when combined with other CNS depressants
• Severe hypotension or cardiovascular events
• Hallucinations or psychotic symptoms

Before prescribing Zolpidem Tartrate, clinicians should consider several safety measures.

• Assess sleep history: confirm that insomnia is appropriate for short‑term pharmacologic therapy.
• Avoid alcohol: concurrent use can intensify sedative effects and impair judgment.
• Use caution in hepatic impairment: reduced metabolism may increase drug exposure.
• Monitor for complex sleep behaviors: educate patients to report unusual activities performed while not fully awake.
• Review concomitant CNS depressants: adjust therapy when used with opioids or benzodiazepines.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Zolpidem Tartrate can interact with several other medicines, influencing its safety and efficacy.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Opioids (e.g., oxycodone, morphine): combined use can cause profound respiratory depression.
• Other CNS depressants (e.g., benzodiazepines, barbiturates): additive sedative effects increase risk of overdose.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels.
• Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants: may enhance sedation.
• Antihistamines and over‑the‑counter sleep aids: monitor for cumulative drowsiness.
• Alcohol: even moderate intake can potentiate sedative action.